ReviewPediatric rheumatology online journal2017
Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis.
Review in Pediatric rheumatology online journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04169828 (The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.Paediatric drugs · 2019Pooled it
- Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial.Rheumatology international · 2022Trial
- A Qualitative Exploration of Adherence to Methotrexate in Juvenile Idiopathic Arthritis.The Journal of pediatrics · 2026Article
- Development and Delivery of an Integrated Digital Health Care Approach for Children With Juvenile Idiopathic Arthritis: Usability Study.JMIR pediatrics and parenting · 2024Article
- International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector.Patient preference and adherence · 2024Article
- Evaluation of Methotrexate Intolerance in Children With Morphea.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis.Paediatric drugs · 2022Article
- SLCO1B1 *15 allele is associated with methotrexate-induced nausea in pediatric patients with inflammatory bowel disease.Clinical and translational science · 2022Article
- Dental caries in children and adolescents with juvenile idiopathic arthritis and controls: a multilevel analysis.BMC oral health · 2021Article
- Coping strategies and anxiety in association with methotrexate-induced nausea in juvenile idiopathic arthritis.Rheumatology international · 2020Observational
- Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance.Pediatric rheumatology online journal · 2020Article
- Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis.Rheumatology (Oxford, England) · 2019Article
- Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients.Pediatric rheumatology online journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients. MAIN BODY: A significant proportion of patients experience nausea and vomiting induced by methotrexate therapy, which can lead to decreased quality of life and discontinuation of treatment with methotrexate. Many strategies have been employed in attempts to reduce methotrexate-induced nausea, including folate supplementation, switching from oral to subcutaneous methotrexate, anti-emetic therapy, behavioral therapy, and others. Anticipatory nausea can be difficult to treat, making primary prevention of nausea with anti-emetics an attractive approach.
conclusionUnderstanding the prevalence and impact of methotrexate-induced nausea, as well as potentially effective interventions, may help maximize the therapeutic benefits of methotrexate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.